Business Description
Collegium Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US19459J1043
Total Employee Number:
423Compare
Compare
Traded in other countries / regions
COLL.USA354.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2015-05-07Description
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.12 | |||||
Equity-to-Asset | 0.15 | |||||
Debt-to-Equity | 3.52 | |||||
Debt-to-EBITDA | 2.83 | |||||
Interest Coverage | 2.06 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 0.83 | |||||
Beneish M-Score | -2.77 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.8 | |||||
3-Year EBITDA Growth Rate | 25.4 | |||||
3-Year EPS without NRI Growth Rate | 23.3 | |||||
3-Year FCF Growth Rate | 31.6 | |||||
3-Year Book Growth Rate | 18.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.71 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 16.46 | |||||
9-Day RSI | 23.81 | |||||
14-Day RSI | 27.72 | |||||
3-1 Month Momentum % | 7.58 | |||||
6-1 Month Momentum % | -13.85 | |||||
12-1 Month Momentum % | -6.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.03 | |||||
Quick Ratio | 0.84 | |||||
Cash Ratio | 0.22 | |||||
Days Inventory | 61.7 | |||||
Days Sales Outstanding | 105.87 | |||||
Days Payable | 10.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 2.2 | |||||
Shareholder Yield % | -3.83 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.02 | |||||
Operating Margin % | 19.48 | |||||
Net Margin % | 5.93 | |||||
EBITDA Margin % | 47.97 | |||||
FCF Margin % | 40.62 | |||||
OCF Margin % | 40.82 | |||||
ROE % | 16.72 | |||||
ROA % | 2.77 | |||||
ROIC % | 8.46 | |||||
3-Year ROIIC % | 110.64 | |||||
ROC (Joel Greenblatt) % | 949.87 | |||||
ROCE % | 12.31 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 20.44 | |||||
Forward PE Ratio | 3.39 | |||||
PE Ratio without NRI | 3.86 | |||||
Price-to-Owner-Earnings | 3.11 | |||||
PEG Ratio | 0.12 | |||||
PS Ratio | 1.19 | |||||
PB Ratio | 2.64 | |||||
Price-to-Free-Cash-Flow | 2.95 | |||||
Price-to-Operating-Cash-Flow | 2.93 | |||||
EV-to-EBIT | 11.63 | |||||
EV-to-EBITDA | 4.62 | |||||
EV-to-Forward-EBITDA | 6.22 | |||||
EV-to-Revenue | 2.22 | |||||
EV-to-Forward-Revenue | 2.2 | |||||
EV-to-FCF | 5.46 | |||||
Price-to-GF-Value | 0.54 | |||||
Price-to-Projected-FCF | 0.26 | |||||
Price-to-Median-PS-Value | 0.52 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.15 | |||||
Earnings Yield (Greenblatt) % | 8.6 | |||||
FCF Yield % | 39.79 | |||||
Forward Rate of Return (Yacktman) % | 41.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:COLL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Collegium Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 808.208 | ||
| EPS (TTM) ($) | 1.24 | ||
| Beta | 0.9337 | ||
| 3-Year Sharpe Ratio | 0.45 | ||
| 3-Year Sortino Ratio | 0.84 | ||
| Volatility % | 51.13 | ||
| 14-Day RSI | 27.72 | ||
| 14-Day ATR ($) | 1.449142 | ||
| 20-Day SMA ($) | 28.74725 | ||
| 12-1 Month Momentum % | -6.39 | ||
| 52-Week Range ($) | 25.16 - 50.7866 | ||
| Shares Outstanding (Mil) | 31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Collegium Pharmaceutical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Collegium Pharmaceutical Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:00 | In 182 days | ||
| Annual report for 2026 | 2027-02-26 | In 181 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 181 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 70 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 69 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:00 | 35.74 (+0.08%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 35.74 (+0.08%) | ||
| Guidance call for 2026 | 2026-06-03 13:20 | 30.48 (-2.93%) | ||
| General meeting for 2026 | 2026-05-14 08:30 | 34.87 (-3.43%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 36.51 (+4.04%) |
Show
Entries
Collegium Pharmaceutical Inc Frequently Asked Questions
What is Collegium Pharmaceutical Inc(COLL)'s stock price today?
The current price of COLL is $25.35. The 52 week high of COLL is $50.79 and 52 week low is $25.16.
When is next earnings date of Collegium Pharmaceutical Inc(COLL)?
The next earnings date of Collegium Pharmaceutical Inc(COLL) is 2026-11-06 Est..
Does Collegium Pharmaceutical Inc(COLL) pay dividends? If so, how much?
Collegium Pharmaceutical Inc(COLL) does not pay dividend.
Guru Commentaries on NAS:COLL
Stone Sentinel Capital
Bearish
2025 Q1
q125
What the manager wrote
Collegium Pharmaceutical (COLL) has executed its playbook well, turning around pharmaceuticals bought at cheap prices and generating excellent cash flows. However, a series of management changes, including the departure of the CEO who executed every M&A deal and the quiet replacement of the Chairman, signal internal conflict about the future of its playbook. While there is optimism about COLL's business model, the manager expresses disappointment with these unexpected management changes, indicating a lack of confidence in the company's leadership.
Press Release
Articles on Collegium Pharmaceutical Inc
A Look at Collegium Pharmaceutical Inc (COLL) After 3.9% Decline -- GF Value $47.17 vs Price $26.39
1 day ago
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers